clinical trial · NCT06824701
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin LymphomaTazemetostatZanubrutinibRituximabObinutuzumab
brief summary
The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
started
Sep 12, 2025
primary completion
Jan 1, 2032
completion
Jan 1, 2033
last updated
Apr 6, 2026
official title
A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol